



IMMUSOFT CORPORATION RAISES \$2.8 MILLION IN SERIES A FUNDING

Patented Hybrid Cell/Gene Therapy Technology Could Treat Serious Genetic Diseases

SAN FRANCISCO, Calif. – March 22, 2017 – [Propel\(x\)](#), the online angel investment platform that helps investors source, evaluate, and fund pioneering science and technology startups, today announced that [Immusoft Corporation](#), a company that is developing a breakthrough platform for treating a variety of genetic diseases through a process called Immune System Programming (ISP™), raised \$2.8 million towards its Series A round with Propel(x) contributing part of the raise from angel investors.

Immusoft was founded by Matthew Scholz, whose initial concept for the core technology was based on using high speed cryptographic hardware to develop novel proteins to fight pathogens. Along the way, Matthew recruited a world-class team of scientists and biotech business experts to build Immusoft's core technology and shape and drive the company. Matthew brings executive leadership experience at startups in several industries, ranging from transportation to technology, enabling him to guide Immusoft as it transitions from a research biotech to a clinical company.

"There is quite an appetite for investing in breakthrough technology that solves some of our greatest problems, and the Propel(x) platform has proven to be a remarkable channel for investors to source incredible deals around the world and invest in some of the most promising, exciting and truly cutting edge companies," said Swati Chaturvedi, CEO of Propel(x).

Immusoft has raised a significant amount to date with notable investors including the Founders Fund, Technium Partners, Breakout Ventures and EB Research.

About the Technology

Immusoft's mission is to treat a variety of human diseases through its breakthrough cell therapy platform called Immune System Programming (ISP™). The ISP™ technology is a hybrid cell/gene therapy approach for safe, reliable insertion of functional genes into immune cells and was designed to address current challenges faced with the production and delivery of conventional protein therapeutic drugs.

The technology can efficiently reprogram a patient's own cells to become miniature drug factories in the body and enables safe insertion of genes encoding the correct human homolog of a missing or defective protein into a patient's immune cells. Once administered back into the patient, the modified cells are expected to live within survival niches in the body, constantly secreting gene-encoded proteins.

"We believe cell therapy is a better way to deliver biologic drug therapies, which in their current state, are challenging to produce at scale. This is because they are difficult to express, require complex purification steps, suffer from stability issues, and often require frequent injections," said Swati Chaturvedi, CEO of Propel(x). "ISP™ can solve many of these current challenges and has the potential to disrupt the current standard of care for many diseases requiring enzyme replacement therapy."

"Successful validation of the ISP platform in human trials would be expected to position Immusoft to successfully build a pipeline of gene-based therapies to treat a number of diseases that currently have no effective therapeutic options," said Matthew Scholz, CEO of Immusoft. "We thank Propel(x) for the opportunity to partner to raise the funds necessary to find viable treatment options for serious diseases in areas of high medical need."

Financing the Future

Propel(x) was founded to help angel investors identify, understand and invest in breakthrough technologies in sectors including life sciences, computer sciences, energy & clean technology, new materials and space. Not only are investors who invest in science and technology companies financing some of most innovative technologies, they are also investing in some of the most lucrative - deep technology companies account for the majority of the DJIA index today.

About Propel(x)

Propel(x) Inc. is an online investment marketplace that connects science and technology startups with angel investors in order to unleash huge innovations, grow great businesses, and have an impact on the way people live. Founded by CEO, Swati Chaturvedi and Lisheng Wang, Propel(x) introduces its members to ground-breaking startups that are developing new forms of clean energy, life-saving drugs, new methods of space exploration, and innovative new materials amongst others. By facilitating private funding for startups based on scientific and technological breakthroughs, Propel(x) seeks to change the world and build the next generation of great companies. For more information, please visit: www.propelx.com.

About Immusoft Corporation

[Immusoft Corporation's](#) mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP™). The technology instructs a patient's cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP™ become miniature drug factories that are expected to survive in patients for many years. Founded in 2009, Immusoft is based in Seattle, Wash.

Contacts

Christine Hardman, 646-277-1286

christine.hardman@icrinc.com